News

George Washington University recently earned a Skin Smart Campus designation, championing skin cancer prevention through education, free sunscreen, and UV safety measures.

Compared to minoxidil alone, the combination therapy saw no significant differences in hair count and diameter.

QRX003 mimics the LEKTI protein to strengthen skin barriers and alleviate symptoms in patients with Netherton Syndrome.

Personalized care is key to managing hyperhidrosis, blending therapies, addressing adverse effects, and empowering patients with tailored solutions.

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, FAAD, presented a case of a man aged 70 years with a 20-year history of psoriasis who was previously treated with adalimumab.

Combining synchronized radiofrequency with high intensity facial electrical stimulation led to firmer, smoother, and more lifted skin.

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

AP31, a novel micropeptide, delivers anti-aging and anti-inflammatory benefits, improving skin firmness, lifting, and reducing wrinkles.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Attovia is also advancing 4 ATTOBODY-based programs for inflammatory conditions, such as atopic dermatitis and IBD.

Adam Friedman, MD, FAAD, takes a closer look at the emerging landscape of oral treatments for hyperhidrosis and what lies ahead in advancing patient care.

Renata Block, MMS, PA-C, and Erica Ramos, PA-C, discuss the complexities of developing an over-the-counter hair product.

These efficacy results and safety profile confirm what was observed in phase 1 study.

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

Researchers found the combination therapy significantly reduced rosacea severity, with 64% achieving mild or normal status in just 4 weeks.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Cytrellis' new president and CEO discusses bridging surgery and innovation in aesthetics.

Patients saw notable improvements in skin hydration, firmness, elasticity, and radiance after 4 and 12 weeks.

Although HA and other methods are safe, more reliable data is needed to determine which is most effective.

Ellacor 2.0 offers advanced micro-coring technology, streamlined protocols, and faster results for non-surgical skin rejuvenation.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

Three posters supporting VP-315's treatment efficacy and outcomes were presented at the Winter Clinical Miami conference.

A recent study found chronic inflammation in psoriasis may contribute to cognitive decline.

Share your thoughts and help shape our content by telling us what topics you want to see more of this year.

When compared to the placebo, hair growth and quality significantly improved by day 180.

Noor emphasizes that patient access is the primary consideration when deciding to use the buy-and-bill model.

In a real-world study, 10 children with generalized pustular psoriasis saw sustained improvements up to 160 weeks.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.